Colinz Laboratories Intrinsic Value
COLINZ Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹39.60 | ₹31.68 - ₹47.52 | -26.8% | EPS: ₹1.80, Sector P/E: 22x |
| Book Value Method | asset | ₹66.67 | ₹60.00 - ₹73.34 | +23.3% | Book Value/Share: ₹33.33, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹40.00 | ₹36.00 - ₹44.00 | -26.0% | Revenue/Share: ₹20.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹33.33 | ₹30.00 - ₹36.66 | -38.4% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹30.95 | ₹24.76 - ₹37.14 | -42.8% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹28.80 | ₹25.92 - ₹31.68 | -46.7% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹26.49 | ₹23.84 - ₹29.14 | -51.0% | Revenue Growth: -3.8%, Adj P/E: 14.7x |
| ROE Based Valuation | profitability | ₹33.33 | ₹30.00 - ₹36.66 | -38.4% | ROE: 10.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹36.74 | ₹33.07 - ₹40.41 | -32.1% | EPS: ₹1.80, BVPS: ₹33.33 |
Want to compare with current market value? Check COLINZ share price latest .
Valuation Comparison Chart
COLINZ Intrinsic Value Analysis
What is the intrinsic value of COLINZ?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Colinz Laboratories (COLINZ) is ₹33.33 (median value). With the current market price of ₹54.07, this represents a -38.4% variance from our estimated fair value.
The valuation range spans from ₹26.49 to ₹66.67, indicating ₹26.49 - ₹66.67.
Is COLINZ undervalued or overvalued?
Based on our multi-method analysis, Colinz Laboratories (COLINZ) appears to be trading above calculated value by approximately 38.4%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Debt to Equity Ratio | 1.20 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 10.0% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.50x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Colinz Laboratories
Additional stock information and data for COLINZ
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |